AN2 Therapeutics Files 8-K on Security Holder Votes & Financials
Ticker: ANTX · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1880438
Sentiment: neutral
Topics: corporate-action, financial-reporting
TL;DR
AN2 Therapeutics filed an 8-K on June 19th covering shareholder votes and financials.
AI Summary
AN2 Therapeutics, Inc. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing date for the report is June 19, 2024. The company is incorporated in Delaware and its principal executive offices are located in Menlo Park, California.
Why It Matters
This filing indicates important corporate actions and financial reporting by AN2 Therapeutics, which could impact investor decisions and the company's operational status.
Risk Assessment
Risk Level: low — This is a routine filing for corporate actions and financial reporting, not indicating immediate operational or financial distress.
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- June 19, 2024 (date) — Date of earliest event reported
- June 24, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Menlo Park, California (location) — Address of Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What financial statements are included in this filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific financial statements are not detailed in the provided text.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on June 19, 2024.
What is the principal executive office address for AN2 Therapeutics, Inc.?
The principal executive office address is 1800 El Camino Real, Suite D, Menlo Park, California, 94027.
What is the SEC file number for AN2 Therapeutics, Inc.?
The SEC file number for AN2 Therapeutics, Inc. is 001-41331.
Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2024-06-24 16:06:01
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value ANTX The Nasdaq Global Se
Filing Documents
- d860451d8k.htm (8-K) — 36KB
- d860451dex31.htm (EX-3.1) — 26KB
- 0001193125-24-166938.txt ( ) — 195KB
- antx-20240619.xsd (EX-101.SCH) — 3KB
- antx-20240619_lab.xml (EX-101.LAB) — 18KB
- antx-20240619_pre.xml (EX-101.PRE) — 11KB
- d860451d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Certificate of Incorporation of AN2 Therapeutics, Inc. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AN2 Therapeutics, Inc. Date: June 24, 2024 By: /s/ Joshua Eizen Joshua Eizen Chief Legal Officer